According to both the companies commercialization of biosimilar products will not follow a pure brand or generic model.
As per the collaboration, Amgen will take up developing, manufacturing and initially commercializing the oncology antibody products.
Watson, on the other hand, will contribute up to $400m in co-development costs over the course of development, including the provision of development support, and will share product development risks.
The products under the deal are likely to be sold under a joint Amgen/Watson label.
Watson will initially receive royalties and sales milestones from product revenues and the collaboration will not pursue biosimilars of Amgen’s proprietary products.